- Home
- FERA vs AQST Comparison
FERA vs AQST Comparison
Compare FERA & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FERA
- AQST
- Stock Information
- Founded
- FERA 2024
- AQST 2004
- Country
- FERA Cayman Islands
- AQST United States
- Employees
- FERA N/A
- AQST N/A
- Industry
- FERA
- AQST Biotechnology: Pharmaceutical Preparations
- Sector
- FERA
- AQST Health Care
- Exchange
- FERA Nasdaq
- AQST Nasdaq
- Market Cap
- FERA 317.4M
- AQST 272.9M
- IPO Year
- FERA 2025
- AQST 2018
- Fundamental
- Price
- FERA N/A
- AQST $3.74
- Analyst Decision
- FERA
- AQST Strong Buy
- Analyst Count
- FERA 0
- AQST 6
- Target Price
- FERA N/A
- AQST $10.67
- AVG Volume (30 Days)
- FERA 5.2K
- AQST 1.5M
- Earning Date
- FERA 01-01-0001
- AQST 08-05-2025
- Dividend Yield
- FERA N/A
- AQST N/A
- EPS Growth
- FERA N/A
- AQST N/A
- EPS
- FERA N/A
- AQST N/A
- Revenue
- FERA N/A
- AQST $54,228,000.00
- Revenue This Year
- FERA N/A
- AQST N/A
- Revenue Next Year
- FERA N/A
- AQST $45.71
- P/E Ratio
- FERA N/A
- AQST N/A
- Revenue Growth
- FERA N/A
- AQST 5.29
- 52 Week Low
- FERA $10.00
- AQST $2.12
- 52 Week High
- FERA $10.60
- AQST $5.80
- Technical
- Relative Strength Index (RSI)
- FERA N/A
- AQST 68.54
- Support Level
- FERA N/A
- AQST $3.13
- Resistance Level
- FERA N/A
- AQST $3.33
- Average True Range (ATR)
- FERA 0.00
- AQST 0.22
- MACD
- FERA 0.00
- AQST 0.01
- Stochastic Oscillator
- FERA 0.00
- AQST 94.10
About FERA Fifth Era Acquisition Corp I Class A Ordinary Shares
Fifth Era Acquisition Corp I is a blank check company.
About AQST Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.